Science & Policy
Weight-loss drugs like Ozempic may also curb drug and alcohol addiction
Summary: GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain.
Key points
- GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain.
- Early trials show reductions in alcohol intake, opioid seeking, and nicotine use.
- Though more research is needed, scientists believe these drugs could open a powerful new front in addiction therapy.
GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain. Early trials show reductions in alcohol intake, opioid seeking, and nicotine use. Though more research is needed, scientists believe these drugs could open a powerful new front in addiction therapy.
Adults 21+. WINDBAR does not sell nicotine products on this site. Compliance statement.